Ever since the CBD pilot program was launched in April by the Centers for Medicare & Medicaid Services (CMS), there has been both excitement and confusion among hemp users, especially those who are also Medicare beneficiaries. If you are enrolled in Medicare, you should learn about the substance access beneficiary engagement incentive (BEI) initiative. Under this program, interested health care providers who participate in select care models can prescribe hemp products worth up to USD $500 a year. However, many factors are involved, such as state rules, safeguards, and monitoring. If you want to use CBD for your health, you must know a few critical aspects.
- Overview of the Substance Access BEI Initiative
Under this engagement model, participating healthcare organizations can provide a limited number of hemp products to eligible beneficiaries, up to a maximum payout limit. However, they must first obtain CMS approval and meet program requirements. For instance, they need a proper implementation program that addresses key areas, including the selection of hemp products and dosage details, the frequency and volume of product distribution, eligibility criteria for patients, monitoring mechanisms, and so on. They must report progress on this front to the relevant authorities and furnish them with supplemental information as needed.
If you want to benefit from CBD Medicare coverage, you must know that the incentive program does not apply to inhalable products, any item that exceeds the permitted maximum THC content, even in oral options, or those that contain artificial cannabinoids. Your healthcare organization must ensure it offers only legal, high-quality hemp products.
- Overview of the Role of Model Participants
Participating healthcare service providers are responsible for supplying ethically produced hemp products to eligible patients. However, the physician must recommend options for eligible patients in line with the model. Paying attention to hemp production rules from federal to local levels is critical. A neutral party should also test these products for potency and potential hazards.
- Overview of the Role of Physicians
It is the physician’s duty to prescribe a specific oral hemp product to a Medicare patient based on the patient’s health condition and through shared decision-making. The patient should be informed of the risks and benefits. In addition, the physicians must listen to their preferences and goals. After reviewing everything, they can suggest a hemp product based on the patient’s current medication regimen.
- Overview of Beneficiary Eligibility
You can use the Medicare Substance Access BEI initiative if you are 18 years old or older. Any disqualifying health condition may make you ineligible for this CBD incentive program. You cannot be breastfeeding or pregnant.
Typically, this pilot program has been launched to help Medicare patients coping with chronic pain, cancer-induced pain, arthritis, sleep disruption, and chemotherapy side effects. However, you don’t qualify for the CBD incentive program just because of your Medicare enrollment or a qualifying medical condition. A set of requirements must be met at all levels. It starts with a health care organization’s participation in a care model and extends to physicians’ affiliation with that entity, and more. You must also know why you are being prescribed a hemp product and what the potential outcomes can be, both positive and negative.
